Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Former Gen-Probe Head Carl Hull Steps Down as Part of Hologic Restructuring


Hologic said this week that Carl Hull will retire from his role as senior vice president and general manager of diagnostics effective on Feb. 15.

Hull previously served as chairman, president, and CEO of Gen-Probe until that company was acquired by Hologic last year in a deal worth an estimated $3.7 billion (PCR Insider, 5/3/2012).

Hologic noted that the mutual agreement with Hull to retire was a result of the company being "ahead of schedule" in the ongoing integration of Gen-Probe and the solid foundation of the current diagnostics business. Hull will continue to serve as a consultant to the company until mid-August.

As part of the ongoing organizational changes, Rohan Hastie, formerly a vice president and general manager within the women's health group of Hologic's diagnostics segment, has been appointed senior vice president and group general manager of diagnostics. This position now includes overseeing the segment's women's health and virology businesses, as well as the US diagnostics sales team, Hologic said.

In addition, Eric Tardif, senior vice president of commercial operations for diagnostics, will assume the role of senior vice president of corporate strategy.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.